Consensus-Based Evaluation of Clinical Significance and Management of Anticancer Drug Interactions

Clinical Therapeutics

Volumn 33, Issue 3, 2011, Pages 305-314

  Jansman, Frank G A ^a,b   Reyners, An K L ^c   van Roon, Eric N ^b,d   Smorenburg, Carolien H ^e   Helgason, Helgi H ^f   le Comte, Marianne ^g   Wensveen, Brigit M ^g   van den Tweel, Annemieke M A ^g,h   de Blois, Mieke ⁱ   Kwee, Wilma ^d   Kerremans, Adrian L ^j   Brouwers, Jacobus R B J ^b,k  

^a DEVENTER HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Zorggroep Noorderbreedte ^*  (Netherlands)

^e Northwest Clinics   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g Royal Dutch Association for the Advancement of Pharmacy   (Netherlands)

^h JEROEN BOSCH HOSPITAL   (Netherlands)

ⁱ CATHARINA HOSPITAL   (Netherlands)

^j ELKERLIEK HOSPITAL   (Netherlands)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Anticancer agents; Clinical effect; Consensus; Drug interactions

Indexed keywords

ALKALOID; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBAMAZEPINE; CLADRIBINE; COTRIMOXAZOLE; COUMARIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PHENYTOIN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TAMOXIFEN; TRIMETHOPRIM; UNINDEXED DRUG; VALPROIC ACID; VINBLASTINE; VINCRISTINE;

ARTICLE; BOOK; CANCER REGISTRY; CLASSIFICATION; DATA BASE; DRUG COMBINATION; DRUG DOSE; DRUG INTERACTION; HOSPITAL PERSONNEL; HUMAN; ONCOLOGY; PHARMACIST;

ANIMALS; ANTINEOPLASTIC AGENTS; CONSENSUS; DRUG INTERACTIONS; DRUG TOXICITY; EXPERT TESTIMONY; HUMANS; NETHERLANDS;

EID: 79956044510     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.022     Document Type: Article

References (27)

1. Mallet L., Spinewine A., Huang A., et al. The challenge of managing drug interactions in elderly people. Lancet 2007, 370:185-191.
2. Blower P., de Wit R., Goodin S., Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized?. Crit Rev Oncol Hematol 2005, 55:117-142.
3. Beijnen J.H., Schellens J.H. Drug interactions in oncology. Lancet Oncol 2004, 5:489-496.
4. Riechelmann R.P., Tannock I.F., Wang L., et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007, 99:592-600.
5. Orale oncolytica in beeld. Pharm Weekbl 2009, 144:13. Stichting Farmaceutische Kengetallen.
6. Bernard S.A., Bruera E. Drug interactions in palliative care. J Clin Oncol 2000, 18:1780-1799.
7. Delafuente J.C. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 2003, 48:133-143.
8. Chan A., Tan S.H., Wong C.M., et al. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A Delphi survey of oncology pharmacists. Clin Ther 2009, 31:2379-2386.
9. McLeod H.L. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998, 45:539-544.
10. Jansman F.G., Jansen A.J., Coenen J.L., et al. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer. Am J Health Syst Pharm 2005, 62:1788-1792.
11. Jansman F.G., Idzinga S.F., Smit W.M., et al. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clin Ther 2005, 27:327-335.
12. Vonbach P., Dubied A., Krähenbühl S., Beer J.H. Evaluation of frequently used drug interaction screening programs. Pharm World Sci 2008, 30:367-374.
13. van Roon E.N., Flikweert S., le Comte M., et al. Clinical relevance of drug-drug interactions: A structured assessment procedure. Drug Saf 2005, 28:1131-1139.
14. Sjöqvist F. Drug Interactions. The Swedish Drug Compendium "FASS" 2000, 1481-1556. LINFO Drug Information Ltd, Stockholm, Sweden.
15. Swen J.J., Wilting I., de Goede A.L., et al. Pharmacogenetics from bench to byte. Clin Pharmacol Ther 2008, 83:781-787.
16. European Medicines Agency European Public Assessment Reports, Accessed October 1, 2010. http://www.ema.europa.eu/htms/human/epar/a.htm.
17. Drug Interaction Facts 2006, Facts and Comparisons, St. Louis, Mo. D.S. Tatro (Ed.).
18. Stockley's Drug Interactions 2007, Pharmaceutical Press, London. 8th ed. K. Baxter (Ed.).
19. Hansten P.D., Horn J.R. Managing Clinically Important Drug Interactions 2009, Facts and Comparisons, St. Louis, Mo.
20. Bornmann L., Illiger H.J., Herdrich K. Drug Interactions in the Therapy of Malignant Diseases, 5th update 2005, Baxter Oncology, Heidelberg, Germany.
21. PubMed. Bethesda, Md: US National Library of Medicine Accessed October 1, 2010. http://www.ncbi.nlm.nih.gov/pubmed/.
22. Embase 2011, Elsevier B.V., Amsterdam, the Netherlands, Accessed October 1, 2010. http://www.embase.com/home.
23. Division of Drug Information Service 2010, Iowa Drug Information Service, University of Iowa, Coralville, Iowa, Accessed October 1, 2010. http://www.uiowa.edu/~idis/idistday.htm.
24. Yap K.Y., Kuo E.Y., Lee J.J., et al. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: An overview of the OncoRx project. Support Care Cancer 2010, 18:883-891.
25. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 2003, National Cancer Institute, Bethesda, Md, Accessed October 1, 2010. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
26. Note for Guidance on the Investigation of Drug Interactions 1997, Committee for Proprietary Medicinal Products, The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, London.
27. Huang S.M., Strong J.M., Zhang L., et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008, 48:612-670.